CN115667251A - 杂芳基衍生物化合物、及其用途 - Google Patents
杂芳基衍生物化合物、及其用途 Download PDFInfo
- Publication number
- CN115667251A CN115667251A CN202280004578.7A CN202280004578A CN115667251A CN 115667251 A CN115667251 A CN 115667251A CN 202280004578 A CN202280004578 A CN 202280004578A CN 115667251 A CN115667251 A CN 115667251A
- Authority
- CN
- China
- Prior art keywords
- pyrimidin
- amine
- phenyl
- alkyl
- isoxazolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
- C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
- C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20210063733 | 2021-05-17 | ||
| KR10-2021-0063733 | 2021-05-17 | ||
| PCT/KR2022/006994 WO2022245085A1 (ko) | 2021-05-17 | 2022-05-16 | 헤테로아릴 유도체 화합물 및 이의 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115667251A true CN115667251A (zh) | 2023-01-31 |
Family
ID=84141801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280004578.7A Pending CN115667251A (zh) | 2021-05-17 | 2022-05-16 | 杂芳基衍生物化合物、及其用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US12037330B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4342895A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7896880B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102607051B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN115667251A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022271388A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022024068A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3180295A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298474A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014887A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI869674B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022245085A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN115667251A (zh) * | 2021-05-17 | 2023-01-31 | 株式会社沃若诺伊生物 | 杂芳基衍生物化合物、及其用途 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106795144A (zh) * | 2014-10-13 | 2017-05-31 | 株式会社柳韩洋行 | 用于调节egfr突变体激酶活性的化合物和组合物 |
| CN111093645A (zh) * | 2017-07-05 | 2020-05-01 | Cs制药技术有限公司 | Egfr酪氨酸激酶的临床上重要的突变体的选择性抑制剂 |
| CN111187221A (zh) * | 2014-10-11 | 2020-05-22 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备和应用 |
| KR20200111644A (ko) * | 2019-03-19 | 2020-09-29 | 보로노이 주식회사 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| WO2020235902A1 (ko) * | 2019-05-17 | 2020-11-26 | 주식회사 보로노이 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL161662A0 (en) | 2001-11-01 | 2004-09-27 | Janssen Pharmaceutica Nv | Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors) |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| TWI389893B (zh) | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
| KR101247840B1 (ko) | 2008-02-22 | 2013-03-26 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타 조절제 |
| US11440899B2 (en) | 2017-10-17 | 2022-09-13 | Merck Patent Gmbh | Pyrimidine TBK/IKKe inhibitor compounds and uses thereof |
| KR20210032093A (ko) | 2019-09-16 | 2021-03-24 | 제이투에이치바이오텍 (주) | Egfr 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도 |
| US20230322753A1 (en) | 2020-09-18 | 2023-10-12 | Voronoi Inc. | Heteroaryl derivative, method for preparation thereof, and pharmaceutical composition comprising same as active ingredient |
| KR20220085735A (ko) | 2020-12-14 | 2022-06-22 | 보로노이바이오 주식회사 | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 |
| US20240262815A1 (en) | 2021-05-07 | 2024-08-08 | Voronoi Inc. | Heteroaryl derivative, method for preparing same, and pharmaceutical composition comprising same as active ingredient |
| CN115667251A (zh) * | 2021-05-17 | 2023-01-31 | 株式会社沃若诺伊生物 | 杂芳基衍生物化合物、及其用途 |
-
2022
- 2022-05-16 CN CN202280004578.7A patent/CN115667251A/zh active Pending
- 2022-05-16 CA CA3180295A patent/CA3180295A1/en active Pending
- 2022-05-16 BR BR112022024068A patent/BR112022024068A2/pt unknown
- 2022-05-16 JP JP2022573567A patent/JP7896880B2/ja active Active
- 2022-05-16 AU AU2022271388A patent/AU2022271388A1/en active Pending
- 2022-05-16 WO PCT/KR2022/006994 patent/WO2022245085A1/ko not_active Ceased
- 2022-05-16 EP EP22793620.0A patent/EP4342895A4/en active Pending
- 2022-05-16 KR KR1020220059638A patent/KR102607051B1/ko active Active
- 2022-05-16 MX MX2022014887A patent/MX2022014887A/es unknown
- 2022-05-16 IL IL298474A patent/IL298474A/en unknown
- 2022-05-16 US US17/927,324 patent/US12037330B2/en active Active
- 2022-05-17 TW TW111118417A patent/TWI869674B/zh active
-
2023
- 2023-11-22 KR KR1020230163623A patent/KR20230163335A/ko active Pending
-
2024
- 2024-01-16 US US18/414,371 patent/US12528799B2/en active Active
- 2024-06-01 US US18/731,285 patent/US12534457B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111187221A (zh) * | 2014-10-11 | 2020-05-22 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备和应用 |
| CN106795144A (zh) * | 2014-10-13 | 2017-05-31 | 株式会社柳韩洋行 | 用于调节egfr突变体激酶活性的化合物和组合物 |
| CN111093645A (zh) * | 2017-07-05 | 2020-05-01 | Cs制药技术有限公司 | Egfr酪氨酸激酶的临床上重要的突变体的选择性抑制剂 |
| KR20200111644A (ko) * | 2019-03-19 | 2020-09-29 | 보로노이 주식회사 | 헤테로아릴 유도체, 이를 제조하는 방법, 및 이를 유효성분으로 포함하는 약학적 조성물 |
| WO2020235902A1 (ko) * | 2019-05-17 | 2020-11-26 | 주식회사 보로노이 | 헤테로고리 융합 피리미딘 유도체 및 이의 용도 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20240317730A1 (en) | 2024-09-26 |
| US12534457B2 (en) | 2026-01-27 |
| TWI869674B (zh) | 2025-01-11 |
| TW202310845A (zh) | 2023-03-16 |
| US20240166640A1 (en) | 2024-05-23 |
| IL298474A (en) | 2023-01-01 |
| US20240025888A1 (en) | 2024-01-25 |
| AU2022271388A1 (en) | 2022-12-01 |
| US12037330B2 (en) | 2024-07-16 |
| KR20220156453A (ko) | 2022-11-25 |
| JP7896880B2 (ja) | 2026-07-29 |
| EP4342895A4 (en) | 2025-09-10 |
| CA3180295A1 (en) | 2022-11-24 |
| BR112022024068A2 (pt) | 2023-12-05 |
| EP4342895A1 (en) | 2024-03-27 |
| KR20230163335A (ko) | 2023-11-30 |
| KR102607051B1 (ko) | 2023-11-30 |
| US12528799B2 (en) | 2026-01-20 |
| WO2022245085A1 (ko) | 2022-11-24 |
| JP2024519626A (ja) | 2024-05-21 |
| MX2022014887A (es) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4615454A1 (en) | Sos1 inhibitors | |
| JP6035423B2 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
| WO2024061333A1 (zh) | 一种kras突变蛋白抑制剂、及其制备方法和应用 | |
| CN105315285B (zh) | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 | |
| CN111936499A (zh) | Mat2a的杂二环抑制剂和用于治疗癌症的方法 | |
| AU2013235344B2 (en) | Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors | |
| CN113993866A (zh) | 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物 | |
| AU2015320142B2 (en) | Novel imidazopyridazine compounds and their use | |
| CA2779105A1 (en) | Kinase inhibitors | |
| EP3556761B1 (en) | Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof | |
| TW202400601A (zh) | 作為parp抑製劑的取代的三環類化合物及其用途 | |
| CN117858877A (zh) | Enl/af9 yeats的c连接抑制剂 | |
| KR20220085735A (ko) | 아이소옥사졸리딘 유도체 화합물 및 이의 용도 | |
| WO2016050171A1 (zh) | 多环类间变性淋巴瘤激酶抑制剂 | |
| US12534457B2 (en) | Heteroaryl derivative compounds, and uses thereof | |
| CN117561058A (zh) | Cdk2抑制剂及其使用方法 | |
| HK40087825A (en) | Heteroaryl derivative compound and use thereof | |
| HK40108597A (en) | Heteroaryl derivative compound and use thereof | |
| EA052736B1 (ru) | Гетероарильные производные и их применение | |
| HK40097521A (en) | Tricyclic compounds and uses thereof | |
| CN120187724A (zh) | 杂芳基衍生物化合物、及其用途 | |
| HK40091563B (en) | Pyrimidinone compounds and uses thereof | |
| WO2025218778A9 (zh) | 杂环化合物及其作为ret抑制剂的用途 | |
| HK40091563A (en) | Pyrimidinone compounds and uses thereof | |
| HK1235786B (en) | Polycyclic anaplastic lymphoma kinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230814 Address after: Inchon City, Korea Applicant after: Voronoy Co.,Ltd. Address before: Inchon City, Korea Applicant before: Voronoi biological Co.,Ltd. Applicant before: Voronoy Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40087825 Country of ref document: HK |
|
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |